How about the effect of thiazolidinediones in diabetic nephropathy?

Medical Science Monitor

Volumn 10, Issue 6, 2004, Pages

  Ina, Keisuke ^a,b  

^a OITA UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE;

CELL PROTECTION; CLINICAL PATHWAY; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MECHANISM; HUMAN; KIDNEY FUNCTION; LETTER; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN;

ALBUMINS; ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY DISEASES; LIPID METABOLISM; RATS; THIAZOLIDINEDIONES;

EID: 3042774549     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Imano E, Kanda T, Nakatani Y et al: Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diab Care, 1998; 21: 2135-39
2. Isshiki K, Haneda M, Koya D et al: Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes, 2000; 49: 1022-32
3. Nakamura T, Ushiyama C, Suzuki S et al: Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diab Med, 2001; 18: 308-13
4. Ueta M, Wakisaka M, Ago T et al: PPARγ ligants attenuate mesangial contractile dysfunction in high glucose. Kidney Int, 2004; 65: 961-71